Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications
Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications
复制标题
DOI：
10.1016/s0968-8080(08)32409-4
复制
发表时间：
2008-11-01
影响因子：
--
通讯作者：
Kim, Sun-Young
中科院分区：
文献类型：
--
作者：
Goldie, Sue J.;O'Shea, Meredith;Kim, Sun-Young
全世界大约70%的宫颈癌病例是由性传播的人乳头瘤病毒（HPV）基因型7 - 6和18引起的。随着针对这些HPV类型的有效疫苗的可用性，有真实的希望减少发展中国家宫颈癌的全球负担。在决定向何处投资以改善健康时，利益攸关方必须考虑宫颈癌相对于其他优先事项造成的疾病负担以及不同干预措施的相对效益。我们进行了一系列分析，为起草免疫政策建议的机构、融资协调机制和国家决策者提供关于HPV 16，18疫苗的益处、成本要求和成本效益的信息。我们发现，在72个最贫穷的国家，中国，泰国以及所有拉丁美洲和加勒比地区，使70%的年轻少女能够获得HPV 16，18疫苗，可以防止未来十年超过400万接种疫苗的妇女死亡。如果每个接种疫苗的女孩的费用低于10 - 25美元，即使在相对贫穷的国家，青少年HPV 16，18疫苗接种也是具有成本效益的。对财政费用和负担能力的关切突出表明，需要降低疫苗价格，建立向青少年提供疫苗的成本效益机制，并创造性地提供资金来源。(C)2008年生殖健康问题。All rights reserved.
Approximately 70% of cases of cervical cancer worldwide are caused by genotypes 7 6 and 18 of human papillomavirus (HPV), which is sexually transmitted. With the availability of an effective vaccine against these HPV types, there is real hope for reducing the global burden of cervical cancer in developing countries. Stakeholders faced with decisions about where to invest money to improve health must consider the burden of disease caused by cervical cancer relative to other priorities and the comparative benefits of different interventions. We conducted a series of analyses to obtain information for agencies drafting immunisation policy recommendations, financing coordination mechanisms, and country decision-makers on the benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine. We found that making an HPV16, 18 vaccine accessible to 70% of young adolescent girls in 72 of the poorest countries, China, Thailand, and all of Latin America and the Caribbean, could prevent the future deaths of more than four million women vaccinated over the next decade. Provided the cost per vaccinated girl is less than $10-$25, adolescent HPV16, 18 vaccination would be cost-effective even in relatively poor countries. Concerns about financial costs and affordability highlight the need for lowering vaccine prices, cost-efficient mechanisms for delivery of vaccinations to adolescents, and creative sources of financing. (C) 2008 Reproductive Health Matters. All rights reserved.